Trust the Science

1. The Sugar Industry Purchases a Scientific Consensus (1967)

Ancel Keys built the dietary fat hypothesis on the Seven Countries Study — a dataset that began with 22 countries and was published with 7. The 15 countries that did not fit the hypothesis, including France and Switzerland with their high-fat, low-heart-disease profiles, were excluded from the published analysis without explanation.

Simultaneously, the Sugar Research Foundation paid Harvard researchers Hegsted and Stare (equivalent to $50,000 in 2016 values) to write a literature review that exonerated sugar and blamed dietary fat. The funding was not disclosed in the New England Journal of Medicine publication.

Western populations responded to the resulting dietary guidelines by replacing fat with sugar and refined carbohydrates. The global type 2 diabetes epidemic follows the same timeline.

2. The Five-Sentence Letter That Killed 500,000 People

In 1980, Porter and Jick published a five-sentence letter in the New England Journal of Medicine noting low addiction rates among hospitalised patients receiving short-term opioids for acute pain. It was not a study. It had no methodology section, no control group, no follow-up.

The letter was cited over 600 times. In 80.8% of those citations, the hospitalised context was not mentioned. In 72.2%, the letter was used as evidence that addiction in opioid use is generally rare. Purdue Pharma trained sales representatives to cite this letter as scientific proof of safety.

Approximately 500,000 people died of opioid overdoses in the United States between 1999 and 2022. Dr. Jick, upon learning of the citation pattern: "I'm essentially mortified that that letter to the editor was used as an excuse to do what these drug companies did."

3. Vioxx: The New England Journal of Medicine Hid Heart Attack Data

In the VIGOR trial — published in the New England Journal of Medicine — Merck's researchers removed cardiovascular endpoints from the manuscript before publication. Patients who suffered serious heart attacks during the trial were not included in the published data. The trial appeared to show Vioxx was safer than standard NSAIDs. It was not.

Merck's internal sales training instructed representatives to "dodge and weave" when physicians asked about cardiac risk. This was documented. In 2005, the NEJM issued a formal Expression of Concern — the journal acknowledging that fatal data had been withheld in its own publication.

Approximately 60,000 people in the United States died of cardiovascular events attributed to Vioxx before it was withdrawn from market in 2004. Merck settled for $4.85 billion.

4. The Alzheimer's Illusion: Sixteen Years Built on Photoshop

In 2006, Sylvain Lesné at the University of Minnesota published research in Nature demonstrating that a specific amyloid-beta protein cluster — Aβ*56 — directly caused Alzheimer's-like dementia in mice. The paper was cited over 2,300 times. It became the empirical foundation for the dominant theory of Alzheimer's disease.

In 2022, Science published a forensic image analysis of the paper. The Western blot images — the hard evidence of protein presence — had been manipulated. Protein bands were copied, repositioned, and pasted to produce the results the hypothesis required.

For sixteen years, the amyloid hypothesis absorbed 99% of Alzheimer's research funding globally. Alternative theories received nothing. Every drug developed on this foundation failed. Patients received pills that did not work, aimed at a target that was not real, based on images that were assembled in Photoshop.

5. Pandemrix: The Hidden Narcolepsy Signal

During the 2009 H1N1 pandemic, European governments purchased Pandemrix from GlaxoSmithKline under emergency conditions. GSK was granted legal immunity from civil liability — the costs of any adverse events would be socialised, while the revenue remained private.

Following the rollout, hundreds of healthy children and adolescents across Europe developed narcolepsy — a debilitating, irreversible neurological disorder caused by autoimmune destruction of orexin-producing neurons. Regulators classified this as coincidence. Official communications did not change.

In 2018, a BMJ investigation obtained internal GSK documents through legal proceedings. The documents showed that GSK had registered an alarming increase in neurological adverse events in its internal safety data at an early stage — and had not shared this with independent physicians or the public. The regulators had not acted on data they did not receive.

6. The Gain-of-Function Network: Concealed Conflicts in the COVID Origins Investigation

On 1 February 2020, a teleconference was held between senior NIH officials — Fauci, Collins, Farrar — and the authors of what would become the most influential paper in the COVID-19 origins debate: "The Proximal Origin of SARS-CoV-2." Three additional scientists were invited by Farrar but were never listed as contributors in the published paper: Ron Fouchier and Marion Koopmans of Erasmus Medical Centre in Rotterdam, and Christian Drosten of the Charité in Berlin. Both Fouchier and Koopmans declined authorship credit because, according to one of the paper's authors, they "opposed scientific articles considering the lab leak theory at all." Their undisclosed contributions and the rationale for concealing them were subsequently confirmed by Freedom of Information Act requests and congressional hearings.

The conflict of interest was structural. Fouchier is Europe's most documented gain-of-function researcher: in 2011, his team at Erasmus MC engineered an airborne-transmissible variant of H5N1 avian influenza — work so controversial that the US National Science Advisory Board for Biosecurity initially recommended blocking publication. Koopmans worked in the same Erasmus MC viroscience department. Their supervisor, Ab Osterhaus, held equity in a vaccine spin-off company while simultaneously advising the Dutch government on pandemic vaccine procurement and chairing an industry-funded WHO advisory body — a conflict documented in the Dutch parliamentary record (2009–2010). Neither Fouchier nor Koopmans disclosed their prior gain-of-function work as a conflict of interest in shaping a paper that evaluated whether gain-of-function research could have produced SARS-CoV-2.

The funding chain that preceded the pandemic has since been formally adjudicated. Peter Daszak, president of EcoHealth Alliance, emailed NIH in July 2016: "We are very happy to hear that our Gain of Function research funding pause has been lifted." This email — obtained through FOIA requests by The Intercept — was his own description of NIH-funded research conducted at the Wuhan Institute of Virology. In 2018, EcoHealth submitted the DEFUSE proposal to DARPA: over $14 million for chimeric bat coronavirus experiments at the WIV using humanised mice. DARPA rejected it, writing that the project "could have put local communities at risk." Fifteen federal agencies received the proposal. None made it public until a DARPA whistleblower disclosed it in 2021. In January 2025, the US Department of Health and Human Services formally debarred EcoHealth Alliance and Dr. Daszak for five years, citing failure "to report dangerous gain-of-function experiments conducted at the Wuhan Institute of Virology."

The most recent development in this network: on 2 June 2026, the US Department of Justice charged Vincent Munster — a 2006 Erasmus MC graduate, former student of Osterhaus and Fouchier, and since 2009 chief of the Virus Ecology Unit at Rocky Mountain Laboratories — with smuggling 113 vials of deactivated monkeypox virus from the Democratic Republic of Congo into the United States and making false statements to federal investigators at Detroit Metropolitan Airport. Munster had "categorically denied" carrying biological material. Lab analysis showed 17 vials contained deactivated mpox virus. The NOS, the Dutch public broadcaster, reported the story on 3 June 2026 — five months after the January arrest.